Can you use weight loss injections with no gallbladder?

Does having no gallbladder change how these medicines work in your body?

Mounjaro (tirzepatide) and Wegovy (semaglutide) both reduce appetite partly by slowing the rate at which the stomach empties. One consequence of this slowing is a change in the normal pattern of bile secretion into the small intestine. In people with an intact gallbladder, bile is concentrated and stored between meals, then released in a controlled surge when fat arrives. After a cholecystectomy, bile drips continuously from the liver into the duodenum because there is no reservoir to hold it. GLP-1 medicines do not restore that reservoir, but they do alter the volume and timing of food reaching the bile, which can shift the digestive pattern further.

For most people who have had a cholecystectomy this does not cause serious problems, and the medicines remain clinically usable. The relationship between weight loss injections and the gallbladder is worth understanding in full, because the concern is not purely about the organ being absent — it is also about what happens in the bile ducts, which remain in place after the gallbladder is removed. Stones can still form in those ducts, and the bile-concentration changes that accompany significant weight loss are a recognised contributing factor, regardless of the treatment method used. The NHS tirzepatide medicines page lists gallbladder problems among the side effects to be aware of, even though the gallbladder is no longer the primary site of concern in someone who has already had it removed.

The practical upshot: absence of a gallbladder does not automatically rule out these medicines, but it is a detail that changes the clinical picture enough to require explicit discussion at consultation.

Why do GLP-1 injections sometimes cause gallbladder problems in the first place?

This question matters for anyone assessing their own risk, gallbladder or not. Rapid weight loss of any kind increases cholesterol concentration in bile, which promotes stone formation. GLP-1 medicines are effective enough that this process can happen faster than it would through diet alone. In the SURMOUNT-1 clinical trial programme, gallbladder-related adverse events were reported at a higher rate in the tirzepatide group than in the placebo group, a pattern consistent with the wider GLP-1 class. You can read more about how weight loss injections can affect the gallbladder and what signs to watch for.

For someone without a gallbladder, the parallel concern is the common bile duct. Bile duct stones (choledocholithiasis) produce symptoms that can look deceptively similar to other gastrointestinal complaints: upper-right abdominal pain, nausea, and occasionally jaundice or fever if a stone causes a blockage. Because GLP-1 side effects already include nausea and gastrointestinal discomfort, there is a risk that a duct-stone symptom gets attributed to the medicine and watched rather than investigated. Telling your prescriber about your cholecystectomy history means they can help you distinguish normal GI adjustment from something that needs urgent evaluation.

Persistent, worsening upper abdominal pain, pain that radiates to the back or right shoulder, or any yellowing of the skin warrants prompt medical attention, not a wait-and-see approach. The page on weight loss injections and gallbladder issues covers these warning signs in more detail.

How does the overlapping symptom picture affect people who've had a cholecystectomy?

Post-cholecystectomy syndrome is the name given to ongoing digestive symptoms that some people experience after gallbladder removal: bloating, loose stools (particularly after fatty meals), and mild upper abdominal discomfort. These occur because the continuous bile drip, without a reservoir to moderate it, can irritate the gut lining. The overlap with GLP-1 side effects is real and worth anticipating.

Nausea, changes in bowel habit, and reduced appetite for fatty foods are common in the early weeks of GLP-1 treatment, typically most noticeable after starting or after a dose step, then settling as the body adjusts. If you already have some post-cholecystectomy digestive sensitivity, the early weeks may feel more pronounced than they would for someone with no surgical history. This does not mean the medicine is doing harm, but it does mean that keeping notes on what you eat, when symptoms occur, and whether they are improving helps your prescribing team make better-informed decisions at your next review.

Staying well hydrated and moderating fat intake in the early weeks of treatment is practical advice our prescribers often discuss with patients who have a history of biliary surgery. Keeping your pen in the fridge door and setting a consistent weekly day for your injection helps you notice any pattern between dosing and symptoms. For a fuller picture of what the evidence says about taking weight loss injections without a gallbladder, that page sets out the clinical considerations in detail. Cost is rarely the first question people with a surgical history ask, but if you want context on what private treatment involves, our guide to weight loss injection costs in the UK explains what a legitimate private prescription includes.

What should you tell your prescriber, and what does the clinical assessment cover?

When you complete a consultation for Mounjaro or Wegovy, your answers about surgical history are read by a GPhC-registered Independent Prescriber, not processed by an algorithm. Cholecystectomy is exactly the kind of detail that shapes the prescriber's assessment: when it happened, whether you still have post-operative symptoms, whether you take ursodeoxycholic acid or any bile-acid sequestrant, and whether your liver function has been checked recently. None of those factors are automatic disqualifiers, but all of them are relevant.

NICE's appraisal of tirzepatide, TA1026, sets out the eligibility framework for tirzepatide within the NHS. Privately, the licensed eligibility is broader: adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition, are potentially suitable, subject to the prescriber's clinical judgement. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. A previous cholecystectomy does not sit on a list of absolute contraindications, but it sits firmly in the category of information your prescriber needs.

If you have questions before starting, our clinical team page explains how the service is structured, and our FAQs cover the most common practical questions. When you are ready, you can speak to our prescribers through a free consultation at our treatment page.